RecruitingPhase 3NCT05856773

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

Phase III Randomized Trial of Conventionally Fractionated vs. Hypofractionated COMprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning PROton Therapy (COMPRO)

Sponsor

Proton Collaborative Group

Enrollment

276 participants

Start Date

Mar 21, 2024

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with breast cancer who require radiotherapy to the breast/chest wall and regional lymph nodes.

Eligibility

Sex: FEMALEMin Age: 19 Years

Inclusion Criteria9

Patients with Stage I-III breast cancer who have undergone breast conserving surgery or mastectomy and have been recommended to receive postoperative radiation therapy to the breast or chest wall and regional draining lymph nodes (axilla levels I-III, SCV, IMN)
Histologically documented breast cancer (invasive mammary, ductal, medullary, tubular, mucinous, lobular, or ductal carcinoma in situ) for which treatment with radiation therapy to the breast/chest wall and comprehensive regional lymph nodes including the internal mammary chain is recommended
Documentation of negative metastatic workup by whole body Positron Emission Tomography - Computed Tomography (PET/CT) or by combined CT of the chest, abdomen, pelvis and Bone scan
History and physical exam within 90 days prior to study registration
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
Negative pregnancy test for women of child-bearing potential
Able to begin radiation treatment within 12 weeks of last surgery or last day of chemotherapy
Presence of breast implants, breast expanders, tissue flap, or other breast reconstruction are allowed
Bilateral breast cancer is allowed if at least one side will be treated with comprehensive nodal irradiation per protocol treatment and will be recorded as the laterality receiving comprehensive nodal irradiation. If both sides will be treated comprehensively, it will be documented as such

Exclusion Criteria12

Presence of skin ulceration and / or ipsilateral satellite nodules and/or edema (including peau d'orange) (T4b or T4c disease) or diagnosis of inflammatory breast cancer (T4d disease)
Residual gross disease detected by imaging or clinical exam with the exception of \<2cm internal mammary lymph node or supraclavicular lymph node amenable to sequential boost
Prior history of radiation therapy overlapping with current target volume (including intraoperative brachytherapy, interstitial catheter brachytherapy, balloon brachytherapy, external beam radiation therapy)
Prior history of explant surgery or implant removal due to infection or wound healing issues without subsequent implant or flap reconstruction
Presence of double/dual port tissue expander
Clinical or radiographic evidence of distant metastatic disease
Pregnant or breast-feeding females
Non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
History of connective tissue disorder (i.e., systemic lupus erythematosus, scleroderma), dermatomyositis, xeroderma pigmentosum
Known BRCA 1 or BRCA 2 mutation
Presence of an active skin rash
Prior invasive non-study malignancy unless disease free for ≥ 3 years. Non-melanoma skin cancer, well-differentiated thyroid cancers, in situ carcinomas of the oral cavity, cervix, and other organs, and tumors that are not thought to impact the life expectancy of the patient are permissible.